Biology of Lymphedema
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Control Study of Pregnancy Complications and Birth Outcomes
Hypertension Research (2011) 34, 55–61 & 2011 The Japanese Society of Hypertension All rights reserved 0916-9636/11 $32.00 www.nature.com/hr ORIGINAL ARTICLE Hypotension in pregnant women: a population-based case–control study of pregnancy complications and birth outcomes Ferenc Ba´nhidy1,Na´ndor A´ cs1, Erzse´bet H Puho´ 2 and Andrew E Czeizel2 Hypotension is frequent in pregnant women; nevertheless, its association with pregnancy complications and birth outcomes has not been investigated. Thus, the aim of this study was to analyze the possible association of hypotension in pregnant women with pregnancy complications and with the risk for preterm birth, low birthweight and different congenital abnormalities (CAs) in the children of these mothers in the population-based data set of the Hungarian Case–Control Surveillance of CAs, 1980–1996. Prospectively and medically recorded hypotension was evaluated in 537 pregnant women who later had offspring with CAs (case group) and 1268 pregnant women with hypotension who later delivered newborn infants without CAs (control group); controls were matched to sex and birth week of cases (in the year when cases were born), in addition to residence of mothers. Over half of the pregnant women who had chronic hypotension were treated with pholedrine or ephedrine. Maternal hypotension is protective against preeclampsia; however, hypotensive pregnant women were at higher risk for severe nausea or vomiting, threatened abortion (hemorrhage in early pregnancy) and for anemia. There was no clinically important difference in the rate of preterm births and low birthweight newborns in pregnant women with or without hypotension. The comparison of the rate of maternal hypotension in cases with 23 different CAs and their matched controls did not show a higher risk for CAs (adjusted OR with 95% confidence intervals: 0.66, 0.49–0.84). -
1 the Physiological and Pathological Functions of VEGFR3 in Cardiac And
Manuscript The physiological and pathological functions of VEGFR3 in cardiac and lymphatic development and related diseases Richard M. Monaghan, Donna J. Page, Pia Ostergaard and Bernard D. Keavney Downloaded from https://academic.oup.com/cardiovascres/advance-article/doi/10.1093/cvr/cvaa291/5926966 by guest on 21 October 2020 Abstract Vascular endothelial growth factor receptors (VEGFRs) are part of the evolutionarily conserved VEGF signalling pathways that regulate the development and maintenance of the body’s cardiovascular and lymphovascular systems. VEGFR3, encoded by the FLT4 gene, has an indispensable and well-characterised function in development and establishment of the lymphatic system. Autosomal dominant VEGFR3 mutations, that prevent the receptor functioning as a homodimer, cause one of the major forms of hereditary primary lymphoedema; Milroy disease. Recently, we and others have shown that FLT4 variants, distinct to those observed in Milroy disease cases, predispose individuals to Tetralogy of Fallot, the most common cyanotic congenital heart disease, demonstrating a novel function for VEGFR3 in early cardiac development. Here, we examine the familiar and emerging roles of VEGFR3 in the development of both lymphovascular and cardiovascular systems, respectively, compare how distinct genetic variants in FLT4 lead to two disparate human conditions, and highlight the research still required to fully understand this multifaceted receptor. key words: angiogenesis and lymphangiogenesis; primary lymphoedema; heart development; vascular endothelial growth factor receptors; congenital heart disease © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. -
Have Already Been Described to Occur with Some
804 Letters, Correspondence, Book reviews have already been described to occur with Correspondence to: Dr D Michel, Service de Neu- some mutations. rologie, Hôpital de Bellevue, 42055 Saint-Etienne, There are only two previous reports Cedex 2, France. relating to three pairs of identical twins with CMT and known genetic defects. In the two 1 Goldsmith P, Rowe D, Jäger R, et al. Focal ver- pairs with the 17p11.2 duplication there was tebral artery dissection causing Brown- remarkable clinical variability.6 We have also Séquard’s syndrome. J Neurol Neurosurg Psy- seen a pair of identical twins with a P0 muta- chiatry 1998;64:415–16. 2 Gutowski NJ, Murphy RP, Beale DJ. Unilateral tion in whom there was marked variability in upper cervical posterior spinal artery syndrome early ages (unpublished data). Apart from the following sneezing. J Neurol Neurosurg Psychia- asymmetry of toe responses in one of the try 1992;55:841–3. probands, the genetically identical twins 3 Bergqvist CAG, Goldberg HI, Thorarensen O, et al. Posterior cervical spinal cord infarction described here are phenotypically very simi- following vertebral artery dissection. Neurology lar, suggesting that the expression of this 1997;48:1112–5. mutation was not influenced by other non- 4 Hundsberger T, Thömke F, Hopf HC, et al. genetic factors. Symmetrical infarction of the cervical spinal cord due to spontaneous bilateral vertebral Codon 39 seems to be of particular Sagittal T2 weighted MRI of the cervicodorsal artery dissection. Stroke 1998;29:1742. importance to Cx32 protein function as cord : high linear signal extending from C4 to 5 Masson C. -
Spinal Cord Injury Manual
Spinal Cord Injury Manual A publication of the Regional Spinal Cord Injury Center of the Delaware Valley The Regional Spinal Cord Injury Center of the Delaware Valley provides a comprehensive program of patient care, community education, and research. It is a federally designated program of Thomas Jefferson University and its affiliated institutions of Thomas Jefferson University Hospital and Magee Rehabilitation Hospital. JG 10-1325 Spinal Cord Injury Patient-Family Teaching Manual A Publication of the Regional Spinal Cord Injury Center of the Delaware Valley Researched and prepared by the clinical personnel of Thomas Jefferson University Hospital and Magee Rehabilitation Hospital Available online at: www.spinalcordcenter.org © 1993, 2001, 2009 Thomas Jefferson University. This publication is the property of Thomas Jefferson University. All rights reserved. This Manual is intended for use in a total system of care that meets all applicable CARF standards for SCI Centers. Neither Thomas Jefferson University Hospital, nor Magee Rehabilitation Hospital is responsible for any liability, claims, demands or damages asserted to be the result, either directly or indirectly, of the information contained herein. The use or reprinting of any part of this manual requires the express permission of Thomas Jefferson University. 3.11.10 3.11.10 Dedication The Handbook Committee of the RSCICDV gratefully acknowledges the assistance and dedication of all who contributed to this manual, and all the others who worked so hard to make this Handbook a reality. -
Brain-To-Cervical Lymph Node Signaling After Stroke
ARTICLE https://doi.org/10.1038/s41467-019-13324-w OPEN Brain-to-cervical lymph node signaling after stroke Elga Esposito1, Bum Ju Ahn1, Jingfei Shi1,2, Yoshihiko Nakamura 1,3, Ji Hyun Park1, Emiri T. Mandeville 1, Zhanyang Yu1, Su Jing Chan 1,4, Rakhi Desai1, Ayumi Hayakawa1, Xunming Ji2, Eng H. Lo1,5*& Kazuhide Hayakawa1,5* After stroke, peripheral immune cells are activated and these systemic responses may amplify brain damage, but how the injured brain sends out signals to trigger systemic inflammation remains unclear. Here we show that a brain-to-cervical lymph node (CLN) 1234567890():,; pathway is involved. In rats subjected to focal cerebral ischemia, lymphatic endothelial cells proliferate and macrophages are rapidly activated in CLNs within 24 h, in part via VEGF-C/ VEGFR3 signalling. Microarray analyses of isolated lymphatic endothelium from CLNs of ischemic mice confirm the activation of transmembrane tyrosine kinase pathways. Blockade of VEGFR3 reduces lymphatic endothelial activation, decreases pro-inflammatory macro- phages, and reduces brain infarction. In vitro, VEGF-C/VEGFR3 signalling in lymphatic endothelial cells enhances inflammatory responses in co-cultured macrophages. Lastly, surgical removal of CLNs in mice significantly reduces infarction after focal cerebral ischemia. These findings suggest that modulating the brain-to-CLN pathway may offer therapeutic opportunities to ameliorate systemic inflammation and brain injury after stroke. 1 Neuroprotection Research Laboratory, Departments of Radiology and Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA. 2 China-America Institute of Neuroscience, Xuanwu Hospital, Capital Medical University, Beijing, China. 3 Department of Emergency and Critical Care Medicine, Fukuoka University Hospital, Jonan, Fukuoka, Japan. -
Human Autoimmunity and Associated Diseases
Human Autoimmunity and Associated Diseases Human Autoimmunity and Associated Diseases Edited by Kenan Demir and Selim Görgün Human Autoimmunity and Associated Diseases Edited by Kenan Demir and Selim Görgün This book first published 2021 Cambridge Scholars Publishing Lady Stephenson Library, Newcastle upon Tyne, NE6 2PA, UK British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library Copyright © 2021 by Kenan Demir and Selim Görgün and contributors All rights for this book reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the copyright owner. ISBN (10): 1-5275-6910-1 ISBN (13): 978-1-5275-6910-2 TABLE OF CONTENTS Preface ...................................................................................................... viii Chapter One ................................................................................................. 1 Introduction to the Immune System Kemal Bilgin Chapter Two .............................................................................................. 10 Immune System Embryology Rümeysa Göç Chapter Three ............................................................................................. 18 Immune System Histology Filiz Yılmaz Chapter Four .............................................................................................. 36 Tolerance Mechanisms and Autoimmunity -
Orthostatic Hypotension in a Cohort of Hypertensive Patients Referring to a Hypertension Clinic
Journal of Human Hypertension (2015) 29, 599–603 © 2015 Macmillan Publishers Limited All rights reserved 0950-9240/15 www.nature.com/jhh ORIGINAL ARTICLE Orthostatic hypotension in a cohort of hypertensive patients referring to a hypertension clinic C Di Stefano, V Milazzo, S Totaro, G Sobrero, A Ravera, A Milan, S Maule and F Veglio The prevalence of orthostatic hypotension (OH) in hypertensive patients ranges from 3 to 26%. Drugs are a common cause of non-neurogenic OH. In the present study, we retrospectively evaluated the medical records of 9242 patients with essential hypertension referred to our Hypertension Unit. We analysed data on supine and standing blood pressure values, age, sex, severity of hypertension and therapeutic associations of drugs, commonly used in the treatment of hypertension. OH was present in 957 patients (10.4%). Drug combinations including α-blockers, centrally acting drugs, non-dihydropyridine calcium-channel blockers and diuretics were associated with OH. These pharmacological associations must be administered with caution, especially in hypertensive patients at high risk of OH (elderly or with severe and uncontrolled hypertension). Angiotensin-receptor blocker (ARB) seems to be not related with OH and may have a potential protective effect on the development of OH. Journal of Human Hypertension (2015) 29, 599–603; doi:10.1038/jhh.2014.130; published online 29 January 2015 INTRODUCTION stabilization, and then at 1 and 3 min after standing. The average of the Orthostatic hypotension (OH) is defined as the reduction in blood last two SBP and DBP values measured in the supine position and the pressure (BP) of at least 20 mmHg systolic and/or 10 mm Hg lowest value during standing were considered. -
Blood Pressure Management
Blood Pressure Management By Karen J. McConnell, Pharm.D., FCCP, BCPS-AQ Cardiology; and William L. Baker, Pharm.D., FCCP, FACC, BCPS, AQ-Cardiology Reviewed by Tyan F. Thomas, Pharm.D., BCPS; and Stacy L. Elder, Pharm.D., BCPS LEARNING OBJECTIVES 1. Distinguish key differences between various national and international hypertension (HTN) guidelines. 2. Demonstrate appropriate drug selection and blood pressure goals for the treatment of HTN according to the presence of concomitant conditions. 3. Devise an evidence-based treatment strategy for resistant HTN to achieve blood pressure goals. 4. Justify the use of ambulatory blood pressure monitoring. 5. Develop treatment strategies for hypertensive urgency and emergency. 6. Construct appropriate drug therapy plans for the treatment of hypotension. 7. Assess the potential effect of pharmacogenomics on blood pressure. EPIDEMIOLOGY ABBREVIATIONS IN THIS CHAPTER Hypertension (HTN) is a persistent, nonphysiologic elevation in blood ABPM Ambulatory blood pressure monitoring pressure; it is defined as (1) having a systolic blood pressure (SBP) ACE Angiotensin-converting enzyme of 140 mm Hg or greater; (2) having a diastolic blood pressure (DBP) AGT Angiotensinogen of 90 mm Hg or greater; (3) taking antihypertensive medication; or ARB Angiotensin receptor blocker (4) having been told at least twice by a physician or other health ASCVD Atherosclerotic cardiovascular professional that one has HTN. According to WHO, almost 1 billion disease people had uncontrolled HTN worldwide in 2008. The American Heart CAD Coronary artery disease Association (AHA) estimates that 41% of the U.S. population will have CCB Calcium channel blocker a diagnosis of HTN by 2030, an increase of 8.4% from 2012 estimates. -
Venous Thromboembolism: Lifetime Risk and Novel Risk Factors A
Venous Thromboembolism: Lifetime risk and novel risk factors A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY Elizabeth Jean Bell, M.P.H. IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY Adviser: Aaron R. Folsom, M.D., M.P.H. March 2015 © Elizabeth Jean Bell 2015 ACKNOWLEDGEMENTS This research was supported by a training grant in cardiovascular disease epidemiology and prevention, funded by the National Institutes of Health. This fellowship has significantly enhanced my doctoral training experience. I could not have completed this research without the support of a great many people. I would first like to thank my advisor, Aaron Folsom. Thank you for taking me on as a mentee, not only at the doctorate level, but also at the master’s level. Undoubtedly you were an influence in my choice to continue my education with a doctorate in the first place. I recognize and appreciate the countless hours you have spent teaching and guiding; thank you for your thorough comments, quick turnaround times, and for always challenging me to achieve. I have learned much from you, including a passion for research. A huge thank you to Pam Lutsey, who has served as an informal mentor to me throughout my master’s and doctorate programs. Thank you for a countless number of things, including guiding my data analyses back before I knew how to do data analyses, sharing your expertise on every paper I have led, and being a role model to aspire to. Thank you to Alvaro Alonso and Saonli Basu, who have each offered their expertise through serving on my doctoral committee. -
The Diagnosis and Treatment of Peripheral Lymphedema: 2016 Consensus Document of the International Society of Lymphology
170 Lymphology 49 (2016) 170-184 THE DIAGNOSIS AND TREATMENT OF PERIPHERAL LYMPHEDEMA: 2016 CONSENSUS DOCUMENT OF THE INTERNATIONAL SOCIETY OF LYMPHOLOGY This International Society of Lymphology “Consensus” of the international community (ISL) Consensus Document is the latest based on various levels of evidence. The revision of the 1995 Document for the document is not meant to override individual evaluation and management of peripheral clinical considerations for complex patients lymphedema (1). It is based upon modifica- nor to stifle progress. It is also not meant to tions: [A] suggested and published following be a legal formulation from which variations the 1997 XVI International Congress of define medical malpractice. The Society Lymphology (ICL) in Madrid, Spain (2), understands that in some clinics the method discussed at the 1999 XVII ICL in Chennai, of treatment derives from national standards India (3), and considered/ confirmed at the while in others access to medical equipment 2000 (ISL) Executive Committee meeting in and supplies is limited; therefore the suggested Hinterzarten, Germany (4); [B] derived from treatments might be impractical. Adaptability integration of discussions and written and inclusiveness does come at the price that comments obtained during and following the members can rightly be critical of what they 2001 XVIII ICL in Genoa, Italy as modified see as vagueness or imprecision in definitions, at the 2003 ISL Executive Committee meeting qualifiers in the choice of words (e.g., the use in Cordoba, Argentina (5); [C] suggested of “may... perhaps... unclear”, etc.) and from comments, criticisms, and rebuttals as mentions (albeit without endorsement) of published in the December 2004 issue of treatment options supported by limited hard Lymphology (6); [D] discussed in both the data. -
Summary of Pure Autonomic Failure
Downloaded from www.dysautonomiainternational.org Summary of Pure Autonomic Failure Pure Autonomic Failure (PAF) is a peripheral degenerative disorder of the autonomic nervous system (ANS).1 PAF was formerly known as Bradbury-Eggleston Syndrome, after the two researchers who first described it in 1925. PAF is also referred to as idiopathic orthostatic hypotension by some physicians.4,6 PAF is one of three diseases classified as a primary autonomic disorder, the other two being Multiple System Atrophy and Parkinson's Disease. Symptoms PAF usually affects more men than women, in middle to later life. However, it is occasionally seen in younger patients.1,2,6 PAF is characterized by orthostatic hypotension (low blood pressure upon standing), a low resting supine plasma noradrenaline concentration that does not increase significantly upon standing,2,3,4 a decreased ability to sweat, persistent neck pain that is often relieved when lying down, raised blood pressure while laying down, changes in urinary habits, and poor tolerance of high altitude. In men with PAF, impotence often occurs.1-6 What Causes PAF? Researchers are not certain of the underlying pathology of PAF yet, but at least in some cases, a loss of nerve cells in the spinal cord has been documented.1,2 Treatment Treatment often focuses on counteracting the effects of orthostatic hypotension, and supine hypertension, which can be difficult.5,6 Patients are often advised to increase fluid and salt intake, wear compression stockings, sleep with the head of their bed at an upright angle, and to use pharmacological options as directed by their physician.1,2,3 Prognosis The prognosis is good for PAF compared to other similar disorders, such as Multiple System Atrophy, with a slower progression and more lifestyle and pharmacological treatment options.1,2,3,4 Most PAF patients survive 20 years or more after diagnosis, many into their 80's.1 The cause of death is often recurrent infection or a pulmonary embolism. -
Hypertensive Urgency (Asymptomatic Severe Hypertension): Considerations for Management
www.RxFiles.ca ‐ updated June 2016 RxFiles Q&A Summary K Krahn , L Regier UofS BSP Student 2014 BSP, BA HYPERTENSIVE URGENCY (ASYMPTOMATIC SEVERE HYPERTENSION): CONSIDERATIONS FOR MANAGEMENT Hypertension is one of the most common chronic medical conditions in Canada. More than one in five Canadians has hypertension and the lifetime risk of developing hypertension is 90%.1 With the addition of comorbid conditions and other risk factors, hypertensive cases can quickly become even more complex. Hypertensive crises include hypertensive urgencies & emergencies. Optimal management lacks conclusive evidence. The rate of associated major adverse cardiovascular events in asymptomatic patients seen in the office are very low.13 Since rapid treatment of hypertensive urgency is not required, some prefer to call it asymptomatic severe hypertension. 1,2,3 ,4,5,6,7,8,9 WHAT IS HYPERTENSIVE URGENCY & HOW DOES IT COMPARE TO HYPERTENSIVE EMERGENCY? The term hypertensive crises can be further divided into hypertensive urgency and hypertensive emergency. The distinction between these two conditions is outlined below.8 Differentiating between these scenarios is essential before initiating treatment. URGENCY 2‐9 EMERGENCY 2‐9 Blood Pressure (mmHg) >180 systolic &/or >120 ‐ >130 CHEP diastolic No Yes: currently experiencing (e.g. aortic dissection, angina/ACS, stroke, Target Organ Damage* encephalopathy, acute renal failure, pulmonary edema, eclampsia) Asymptomatic; or severe headache, shortness Shortness of breath, chest pain, numbness/weakness, change in Symptoms of breath, nosebleeds, severe anxiety vision, back pain, difficulty speaking *Note: Signs of end‐organ damage/dysfunction may occur at a lower blood pressure in pregnant & pediatric patients Initial Patient Work‐Up to Differentiate between Urgency and Emergency: Verify blood pressure (BP) reading(s).